Interpore Cross Cited For BonePlast Journal Ad In FDA Warning Letter
This article was originally published in The Gray Sheet
Executive Summary
Interpore Cross may face FDA misbranding and adulteration actions if the company provides reprints of journal articles detailing use of the firm's BonePlast bone void filler with antibiotics, growth factors or other therapeutics.